Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

DNA 'Crystal Ball' may spot return of colorectal cancer

NCT ID NCT06314958

Knowledge-focused Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study aims to develop a test that uses DNA methylation patterns from tumor samples to predict whether stage II or III colorectal cancer will return after surgery and chemotherapy. Researchers will analyze tissue from 400 patients who are currently cancer-free after treatment. The goal is to create a tool that identifies patients at higher risk of recurrence, potentially guiding more personalized follow-up care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a blood or tissue test that helps doctors know which patients need closer monitoring after colorectal cancer treatment.
What could go wrong
This is an early-stage study focused on developing and validating a test, not a treatment. The test may not prove accurate enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Two independent cohorts of colorectal cancer survivors (high-risk stage II and stage III), who received curative-intent surgery and adjuvant chemotherapy

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Stage II (high-risk) or III colorectal cancer (TNM classification, 8th edition). * Received standard diagnostic, staging, and therapeutic procedures as per local guidelines * Received stage-specific curative-intent resection followed by adjuvant chemotherapy. * Confirmed cancer-free survivorship confirmed at the time of study inclusion. Exclusion Criteria: * Lack of written informed consent. * Development of recurrence in the first 6 months following adjuvant chemotherapy completion. * Hereditary colorectal cancer syndromes (identified through genetic testing) * Inflammatory bowel diseases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal carcinoma colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal adenocarcinoma Colorectal cancer Colorectal cancer recurrent Colorectal cancer stage II Colorectal cancer stage III

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Barcelona University

    RECRUITING

    Barcelona, Spain

  • City of Hope Medical Center

    RECRUITING

    Monrovia, California, 91016, United States

  • La Paz University Hospital

    RECRUITING

    Madrid, Spain

  • Second Affiliated Hospital of Dalian Medical University

    RECRUITING

    Dalian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.